Consolidation chemotherapy with capecitabine after neoadjuvant chemoradiotherapy in high-risk patients with locally advanced rectal cancer: Propensity score study

Figure 1 Histograms and density graphs description comparisons of the original, propensity score match and inverse probability of treatment weighting distributions in the consolidation chemotherapy and non-consolidation chemotherapy groups. PSM: Propensity score match; IPTW: Inverse probability of treatment weighting; CC: Consolidation chemotherapy.

Figure 2 Forest plot of the subgroup analysis for complete response rate in the propensity score match cohort. Odds rate (OR) > 1 favors consolidation chemotherapy (CC) group, and OR < 1 favors non-CC group. CR: complete response; PSM: Propensity score match; CC: Consolidation chemotherapy; OR: Odds rate; CI: Confident interval; CEA: Carcinoma embryonic antigen; MRF: Mesorectal fascia; EMVI: Extralmural venous invasion.

Figure 3 Non-regrowth disease free survival and overall survival of consolidation chemotherapy and non-consolidation chemotherapy groups. A: Non-regrowth disease free survival (NR-DFS) before matching; B: Overall survival (OS) before matching; C: NR-DFS after propensity score match (PSM); D: OS after PSM; E: NR-DFS after inverse probability of treatment weighting (IPTW); F: OS after IPTW. CC: Consolidation chemotherapy.